Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Inclusion Criteria

• •1. Signed Informed Consent Form available
• •2. Patients ≥ 18 years and ≤75years of age at time of signing Informed Consent Form
• •3. Diagnosis of HCC confirmed by histology
• •4. Initially resectable with high-risk recurrence factors. High-risk features for resected patients include tumor size \>5 cm, tumor number \>3, vascular invasion (microvascular invasion or macrovascular invasion - Vp1/Vp2 - of the portal vein) and poor tumor differentiation (defined as Grade 3 or 4).
• •Up to three tumors, with largest tumor \>5 cm regardless of vascular invasion (microvascular invasion or macrovascular invasion of Vp1/Vp2) or poor tumor differentiation (Grade 3 or 4) Four or more tumors, with largest tumor ≤5 cm regardless of vascular invasion (microvascular invasion or macrovascular invasion of Vp1/Vp2) or poor tumor differentiation (Grade 3 or 4) Up to three tumors, with largest tumor ≤5 cm with vascular invasion (microvascular invasion or macrovascular invasion of Vp1/Vp2) and/or poor tumor differentiation (Grade 3 or 4)
• •5. Measurable disease (at least one target lesion) according to RECIST v1.1 as determined by the investigator
• •6. Child-Pugh A
• •7. ECOG PS 0～1
• •8. No prior locoregional or systemic treatment for HCC
• •9. Negative HIV test at screening